NSCLC cells treated with Gefitinib - refine.bio

GSE23206

Homo sapiens

2 Downloadable Samples

Technology Badge Icon

Affymetrix Human Genome U133 Plus 2.0 Array (hgu133plus2)

Submitter Supplied Information

Description

About 10% of all NSCLC patients respond to gefitnib treatment and all of these patients will acquire resistance to the EGFR TKI.

PubMed ID

Publication Title

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Total Samples

2

Submitter’s Institution

University of Colorado Denver

Authors

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE

Source Repository

Gene Expression Omnibus (GEO)

No rows found

Loading...